Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

WPD 401

Drug Profile

WPD 401

Alternative Names: Interceptor - WPD Pharmaceuticals; Meteor - WPD Pharmaceuticals; WPD-401; WPD-402

Latest Information Update: 09 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator WPD Pharmaceuticals
  • Class Antineoplastics; Biological toxins; Recombinant fusion proteins
  • Mechanism of Action EphA2 receptor antagonists; EphA3 receptor antagonists; Ephrin-B2 antagonists; Interleukin 13 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Glioblastoma

Most Recent Events

  • 31 Jan 2024 Early research in Glioblastoma in Poland (unspecified route) prior to January 2024
  • 31 Jan 2024 Preclinical trials in Breast cancer in Poland (IV)
  • 05 Oct 2021 WPD Pharmaceuticals and Wake Forest University has patent protection for multi-level specific targeting of cancer cells in the US
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top